Suppression of the mTOR-raptor signaling pathway by the inhibitor of heat shock protein 90 geldanamycin

被引:47
作者
Ohji, G
Hidayat, S [1 ]
Nakashima, A
Tokunaga, C
Oshiro, N
Yoshino, K
Yokono, K
Kikkawa, U
Yonezawa, K
机构
[1] Kobe Univ, Biosignal Res Ctr, Kobe, Hyogo 6578501, Japan
[2] Japan Sci & Technol Agcy, CREST, Kawaguchi, Saitama 3320012, Japan
[3] Kobe Univ, Grad Sch Med, Dept Dev & Aging, Div Internal & Geriatr Med, Kobe, Hyogo 6500017, Japan
关键词
geldanamycin; Hsp90; mTOR; protein phosphorylation; raptor;
D O I
10.1093/jb/mvj008
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Heat shock protein 90 (Hsp90) was co-immunoprecipitated with raptor, the binding partner of the mammalian target of rapamycin (mTOR) from HEK293 cells. Hsp90 was detected in the anti-raptor antibody immunoprecipitates prepared from the cell extract by immunoblot analysis using the anti-Hsp90 antibody, and the association of these two proteins was confirmed by immunoprecipitation from the cells co-expressing Hsp90 and raptor as epitope-tagged molecules. Geldanamycin, a potent inhibitor of Hsp90, disrupted the in vivo binding of Hsp90 to raptor without affecting the association of raptor and mTOR, and suppressed the phosphorylation by mTOR of the downstream translational regulators p70 S6 kinase (S6K) and eukaryotic initiation factor 4E-binding protein 1 (4E-BP1). The protein kinase activity of S6K as well as the phosphorylation of the substrate, 40S ribosomal protein S6, were lowered in the geldanamycin-treated cells. These results indicate that Hsp90 is involved in the regulation of protein translation by facilitating the phosphorylation reaction of 4E-BP1 and S6K catalyzed by the mTOR/raptor complex through the association with raptor, and that the mTOR signaling pathway is a novel target of geldanamycin.
引用
收藏
页码:129 / 135
页数:7
相关论文
共 41 条
[1]   3 Phosphoinositide-dependent protein kinase 1 (PDK1) phosphorylates and activates the p70 S6 kinase in vivo and in vitro [J].
Alessi, DR ;
Kozlowski, MT ;
Weng, QP ;
Morrice, N ;
Avruch, J .
CURRENT BIOLOGY, 1998, 8 (02) :69-81
[2]  
Avruch J, 2001, Prog Mol Subcell Biol, V26, P115
[3]  
BANDI HR, 1993, J BIOL CHEM, V268, P4530
[4]   The TOR pathway: A target for cancer therapy [J].
Bjornsti, MA ;
Houghton, PJ .
NATURE REVIEWS CANCER, 2004, 4 (05) :335-348
[5]   CONTROL OF P70 S6 KINASE BY KINASE-ACTIVITY OF FRAP IN-VIVO [J].
BROWN, EJ ;
BEAL, PA ;
KEITH, CT ;
CHEN, J ;
SHIN, TB ;
SCHREIBER, SL .
NATURE, 1995, 377 (6548) :441-446
[6]   Rheb binds tuberous sclerosis complex 2 (TSC2) and promotes S6 kinase activation in a rapamycin- and farnesylation-dependent manner [J].
Castro, AF ;
Rebhun, JF ;
Clark, GJ ;
Quilliam, LA .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (35) :32493-32496
[7]   Phosphorylation of mammalian target of rapamycin (mTOR) at ser-2448 is mediated by p70S6 kinase [J].
Chiang, GG ;
Abraham, RT .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (27) :25485-25490
[8]  
DOSSARBASSOV D, 2005, SCIENCE, V307, P1098
[9]   Mammalian target of rapamycin (mTOR) inhibitors [J].
Dutcher J.P. .
Current Oncology Reports, 2004, 6 (2) :111-115
[10]   Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression [J].
Fingar, DC ;
Blenis, J .
ONCOGENE, 2004, 23 (18) :3151-3171